FDA Advisory Panel Votes on Avandia
A Food and Drug Administration advisory panel recently voted to keep the GlaxoSmithKline drug Avandia on the market. The diabetes medication has come under fire recently for allegations that it can increase the risk of heart attack for users. The panel first voted 21-4 that Avandia is more likely to cause heart attack than its closest competitor Actos (8 panelists deferred the vote citing there wasn’t enough information available to make a decision).
The panel then voted 21-12 that Avandia stay on the market while 10 also suggested that restrictions be placed on the prescription. The FDA is not required to follow the advisory panel’s advice, but they usually do.
GlaxoSmithKline is already facing numerous lawsuits alleging that Avandia caused the heart attacks or strokes of users. Despite the FDA panel win, experts predict that prescriptions for the drug will drop dramatically as the law suits approach.